Open-label, Single-arm, Multiple-dose Safety, Titration, and Pharmacokinetic Trial of Afrezza in Pediatric Patients Ages 4 to 17 Years With Type 1 Diabetes Mellitus

Trial Profile

Open-label, Single-arm, Multiple-dose Safety, Titration, and Pharmacokinetic Trial of Afrezza in Pediatric Patients Ages 4 to 17 Years With Type 1 Diabetes Mellitus

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Insulin (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors MannKind Corporation
  • Most Recent Events

    • 27 Sep 2017 Status changed from not yet recruiting to recruiting.
    • 22 Aug 2017 Planned initiation date changed from 1 Aug 2015 to 1 Sep 2017.
    • 22 Aug 2017 Planned End Date changed from 1 Aug 2017 to 1 Jan 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top